Brain Connectivity Scans for Early Detection of Alzheimer's Disease
Tests whether brain connectivity changes can predict Alzheimer's disease in adults aged 40 to 85.
Plain-language title generated from the registry record
Registry title: Brain Connectivity Marker for Alzheimer's Disease
Key facts
- Where
- Stockholm, SwedenSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 85 years old?
Source: NCT06874231, who can take part
Where in Sweden
- Karolinska University HospitalStockholm, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Karolinska Institutet
- Trial code
- NCT06874231
- Record updated
- 17 March 2025
- Original description
The main purpose of this project is to establish whether changes in brain connectivity can be used to predict the development of Alzheimer's disease (AD).Read full original descriptionShow less
Clinical Application of a Brain Connectivity Marker for Early Detection of Alzheimer's Disease
The main purpose of this project is to establish whether changes in brain connectivity can be used to predict the development of Alzheimer's disease (AD).
Inclusion: Inclusion criteria for subjects with subjective cognitive complaints:; MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 26 and 30; Absence of cognitive impairment; Memory problems reported by the participant/family member; Do not fulfill criteria for mild cognitive impairment or dementia; Must speak and understand Swedish; Inclusion criteria for patients with mild cognitive impairment:; MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 24 and 30; Impaired memory function; Do not fulfill criteria for dementia; Must speak and understand Swedish; Must have abnormal cerebrospinal fluid amyloid-β 42/40 ratio levels, which is a biomarker of Alzheimer's disease; Specific inclusion criteria for patients with Alzheimer's disease:; MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 18 and 28; Impaired memory function in addition to impaired executive abilities, language function, visuospatial ability and/or attention/psychomotor speed; Meet NINCDS-ADRDA and DSM-IV criteria for probable Alzheimer's disease; Must speak and understand Swedish; Must have abnormal spinal fluid amyloid-β 42/40 ratio levels, which is a biomarker of Alzheimer's disease.
Exclusion: Alcohol or drug abuse; Refuse to cerebrospinal fluid testing and/or blood sampling, neuropsychological testing, brain imaging, electroencephalogram or magnetoencephalogram; In addition, participants who have claustrophobia or some form of metal implant in their body that may interfere with the brain imaging scan will be excluded from the study; Unstable somatic disease or organ failure.